Literature DB >> 23242157

Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort.

Benjamin B Gelman1, Joshua G Lisinicchia, Susan Morgello, Eliezer Masliah, Deborah Commins, Cristian L Achim, Howard S Fox, Dennis L Kolson, Igor Grant, Elyse Singer, Constantin T Yiannoutsos, Seth Sherman, Gary Gensler, David J Moore, Tiansheng Chen, Vicki M Soukup.   

Abstract

OBJECTIVE: Replicating HIV-1 in the brain is present in HIV encephalitis (HIVE) and microglial nodule encephalitis (MGNE) and is putatively linked with HIV-associated neurocognitive disorders (HAND). A cliniconeurovirological correlation was conducted to elucidate the relationship between brain viral load and clinical phenotype. SUBJECTS AND ASSAYS: HIV gag/pol RNA and DNA copies were quantified with reverse transcriptase-polymerase chain reaction or polymerase chain reaction in 148 HAART-era brain specimens. Comparison with HAND, HIVE, and MGNE and correlation with neuropsychological (NP) test scores were done using one-way ANOVA with Tukey-Kramer and Spearman tests, respectively.
RESULTS: Brain HIV RNA was higher in subjects with HAND plus HIVE versus without HAND (delta = 2.48 log10 units, n = 27 versus 36, P < 0.001). In HAND without HIVE or MGNE, brain HIV RNA was not significantly different versus without HAND (P = 0.314). Worse NP scores correlated significantly with higher HIV RNA and interferon responses in brain specimens (P < 0.001) but not with HIV RNA levels in premortem blood plasma (n = 114) or cerebrospinal fluid (n = 104). In subjects with MGNE, brain HIV RNA was slightly higher versus without MGNE (P < 0.01) and much lower versus with HIVE (P < 0.001).
CONCLUSIONS: Brain HIV RNA and to a lesser extent HIV DNA are correlated with worse NP performance in the 6 months before death. Linkage occurs primarily in patients with HIVE and MGNE, and these patients could obtain added NP improvement by further reducing brain HIV while on HAART. Patients not in those groups are less certain to obtain added NP benefit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23242157      PMCID: PMC3664102          DOI: 10.1097/QAI.0b013e31827f1bdb

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  38 in total

1.  HIV infection and dementia.

Authors:  S Gartner
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

2.  Changes in pathological findings at autopsy in AIDS cases for the last 15 years.

Authors:  E Masliah; R M DeTeresa; M E Mallory; L A Hansen
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

3.  Peripheral administration of lipopolysaccharide induces activation of microglial cells in rat brain.

Authors:  M Buttini; S Limonta; H W Boddeke
Journal:  Neurochem Int       Date:  1996-07       Impact factor: 3.921

4.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

5.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; K Hsia; S A Spector; J A Nelson; R K Heaton; M R Wallace; I Abramson; J H Atkinson; I Grant; J A McCutchan
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

6.  HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement.

Authors:  J E Bell; R P Brettle; A Chiswick; P Simmonds
Journal:  Brain       Date:  1998-11       Impact factor: 13.501

Review 7.  The neuropathogenesis of HIV-1 infection.

Authors:  H E Gendelman; S A Lipton; M Tardieu; M I Bukrinsky; H S Nottet
Journal:  J Leukoc Biol       Date:  1994-09       Impact factor: 4.962

Review 8.  Simian immunodeficiency virus: a model for neuroAIDS.

Authors:  H S Fox; L H Gold; S J Henriksen; F E Bloom
Journal:  Neurobiol Dis       Date:  1997       Impact factor: 5.996

9.  Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.

Authors:  J D Glass; H Fedor; S L Wesselingh; J C McArthur
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

10.  Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.

Authors:  Benjamin B Gelman; Joshua G Lisinicchia; Tianshen Chen; Kenneth M Johnson; Kristofer Jennings; Daniel H Freeman; Vicki M Soukup
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-06       Impact factor: 4.147

View more
  71 in total

Review 1.  Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment.

Authors:  Hyeon-Sook Suh; Benjamin B Gelman; Sunhee C Lee
Journal:  J Neuroimmune Pharmacol       Date:  2014-03       Impact factor: 4.147

2.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 3.  Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.

Authors:  Jay Rappaport; David J Volsky
Journal:  J Neurovirol       Date:  2015-05-02       Impact factor: 2.643

4.  Progressive brain atrophy in chronically infected and treated HIV+ individuals.

Authors:  Talia M Nir; Neda Jahanshad; Christopher R K Ching; Ronald A Cohen; Jaroslaw Harezlak; Giovanni Schifitto; Hei Y Lam; Xue Hua; Jianhui Zhong; Tong Zhu; Michael J Taylor; Thomas B Campbell; Eric S Daar; Elyse J Singer; Jeffry R Alger; Paul M Thompson; Bradford A Navia
Journal:  J Neurovirol       Date:  2019-02-14       Impact factor: 2.643

5.  HIV protease inhibitor exposure predicts cerebral small vessel disease.

Authors:  Virawudh Soontornniyomkij; Anya Umlauf; Sandra A Chung; Megan L Cochran; Benchawanna Soontornniyomkij; Ben Gouaux; Will Toperoff; David J Moore; Eliezer Masliah; Ronald J Ellis; Igor Grant; Cristian L Achim
Journal:  AIDS       Date:  2014-06-01       Impact factor: 4.177

Review 6.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

7.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

Review 8.  Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model.

Authors:  Dianne Langford; Byung Oh Kim; Wei Zou; Yan Fan; Pejman Rahimain; Ying Liu; Johnny J He
Journal:  J Neurovirol       Date:  2017-11-15       Impact factor: 2.643

Review 9.  HIV Eradication Strategies: Implications for the Central Nervous System.

Authors:  Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

10.  Modeling brain lentiviral infections during antiretroviral therapy in AIDS.

Authors:  Weston C Roda; Michael Y Li; Michael S Akinwumi; Eugene L Asahchop; Benjamin B Gelman; Kenneth W Witwer; Christopher Power
Journal:  J Neurovirol       Date:  2017-05-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.